Dr. Reddy's Reports Q1 FY27 Consolidated Results and Announces Global Biologics Head Appointment

Dr. Reddy's Reports Q1 FY27 Consolidated Results and Announces Global Biologics Head Appointment​

Dr. Reddy's Laboratories Ltd. announced its consolidated financial results for the quarter ended June 30, 2026, reporting revenues of 80,705 million INR. The company also confirmed the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and detailed the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm.

The results for the quarter reflected a decline in consolidated revenues year-over-year but noted underlying double-digit growth in the base business across various geographies. The company also reported specific operational impacts related to production and market conditions during Q1 FY27 (Q1FY27).

Financial Performance Highlights​

Consolidated financial results for Dr. Reddy's Laboratories Ltd. under International Financial Reporting Standards (IFRS) showed the following key figures:


The company reported that the results included a provision of 2,397 million INR towards inventory and associated costs stemming from batches of Semaglutide found out of specification due to an issue with the active pharmaceutical ingredient (API).

Segmental Performance Overview​

Segment wise revenues showed diverse performance across different markets:


The Global Generics segment accounted for the majority of consolidated revenue (89%) and reported revenues at 72.0 billion INR, showing a decline of 5% year-over-year (YoY) but growing 9% quarter-on-quarter (QoQ).

Operational Focus and Governance Updates​

Appointment of Global Head of Biologics
The Board of Directors approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. She was also inducted as a Member of the Management Council.

Dr. Sridevi Khambhampaty's profile highlights over two decades of experience in Biologics R&D, Quality, and Business leadership, including previous roles at Shilpa Biologics, Syngene International, and Intas Biopharma.

Statutory Auditor Appointment
The Board of Directors approved the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm. This firm will serve for a term of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to shareholder approval at the ensuing Annual General Meeting (AGM).

Other Financial and Operational Details​

The company noted several operational impacts that contributed to the financial results:

• Product Impairment: A net loss of 1,350 million INR was recognized in the Global Generic segment due to the discontinuation of certain R&D programs related to Chimeric Antigen Receptor T-cell (CAR-T) therapy.
• Market Adjustments: During Q1 FY27, a reduction of 4,530 million INR from "Revenue from operations" in the Global Generics Segment was recorded due to price reductions for its generic product Lenalidomide in the United States.

Senior Management Team Composition​

The updated list of Senior Management Personnel includes Dr. Sridevi Khambhampaty as Global Head of Biologics (Sl.No. 14). Other key personnel listed include Mr. G V Prasad as Co-Chairman and Managing Director, Mr. Erez Israeli as Chief Executive Officer, and Mr. M V Narasimham as Chief Financial Officer (CFO).

DRREDDY Stock Price Movement​

Shares of Dr. Reddy's Laboratories Limited shed 2.16% on Wednesday, settling at ₹1182.8 after trading down by ₹26.10 from its previous close. The stock saw significant intraday volatility, which encompassed a trading range between ₹1169 and ₹1202.3, with a total traded volume of 2,528,082 shares recorded.